enGene (NASDAQ:ENGN) Coverage Initiated at Guggenheim

Equities research analysts at Guggenheim assumed coverage on shares of enGene (NASDAQ:ENGN) in a report released on Monday, MarketBeat reports. The firm set a “buy” rating and a $34.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 117.95% from the company’s previous close.

ENGN has been the topic of a number of other research reports. UBS Group began coverage on enGene in a research note on Thursday, March 28th. They issued a “buy” rating and a $37.00 target price on the stock. Morgan Stanley assumed coverage on enGene in a report on Friday, March 8th. They issued an “overweight” rating and a $40.00 price target for the company. Leerink Partnrs reissued an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. Finally, SVB Leerink began coverage on enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $35.50.

enGene Trading Down 1.2 %

enGene stock opened at $15.60 on Monday. The company’s 50-day moving average price is $15.55. enGene has a fifty-two week low of $6.69 and a fifty-two week high of $43.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Blue Owl Capital Holdings LP purchased a new position in shares of enGene during the fourth quarter worth $11,397,000. Royal Bank of Canada purchased a new position in shares of enGene during the fourth quarter worth $349,000. Goldman Sachs Group Inc. purchased a new position in shares of enGene during the fourth quarter worth $346,000. Citadel Advisors LLC purchased a new position in shares of enGene during the fourth quarter worth $185,000. Finally, BVF Inc. IL acquired a new stake in shares of enGene in the fourth quarter valued at $20,777,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.